Axsome Therapeutics (AXSM) reported second-quarter 2026 total net product revenue of $218.4 million, up 46% year over year, led by AUVELITY net product sales of $180.3 million. SUNOSI net product revenue was $35.8 million, and SYMBRAVO net product sales were $2.3 million.
The company reported a second-quarter net loss of $51.3 million, or $0.99 per share, and cash and cash equivalents of $319.9 million at June 30, 2026. Axsome also said the FDA accepted the AXS-12 NDA for cataplexy in narcolepsy with a PDUFA target action date of May 1, 2027.
- Total net product revenue rose 46% year over year to $218.4 million.
- AUVELITY net product sales increased 51% year over year to $180.3 million.
- SUNOSI net product revenue increased 20% year over year to $35.8 million.
- SYMBRAVO net product sales were $2.3 million after its June 2025 launch.
- Axsome launched AUVELITY for agitation associated with dementia due to Alzheimer’s disease in June 2026.
- The company initiated FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD.
$AXSM Insider Trading Activity
$AXSM insiders have traded $AXSM stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:
- HERRIOT TABUTEAU (Chief Executive Officer) has made 0 purchases and 4 sales selling 149,000 shares for an estimated $34,441,528.
- MARK COLEMAN has made 0 purchases and 5 sales selling 43,180 shares for an estimated $8,207,327.
- NICK PIZZIE (Chief Financial Officer) sold 33,000 shares for an estimated $7,922,970
- MARK L. JACOBSON (Chief Operating Officer) has made 0 purchases and 3 sales selling 40,128 shares for an estimated $6,809,761.
- ARI MAIZEL (Chief Commercial Officer) sold 7,500 shares for an estimated $1,368,150
- SUSAN MAHONY has made 0 purchases and 2 sales selling 600 shares for an estimated $145,017.
- ROGER JEFFS has made 0 purchases and 2 sales selling 572 shares for an estimated $141,655.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AXSM Hedge Fund Activity
We have seen 219 institutional investors add shares of $AXSM stock to their portfolio, and 193 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP removed 888,001 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $150,089,929
- BLACKROCK, INC. removed 809,136 shares (-20.7%) from their portfolio in Q2 2026, for an estimated $198,052,218
- FIRST TRUST ADVISORS LP added 534,066 shares (+1230.2%) to their portfolio in Q1 2026, for an estimated $90,267,835
- ROCKEFELLER CAPITAL MANAGEMENT L.P. removed 414,419 shares (-99.1%) from their portfolio in Q1 2026, for an estimated $70,045,099
- ASSENAGON ASSET MANAGEMENT S.A. removed 411,276 shares (-47.5%) from their portfolio in Q2 2026, for an estimated $100,668,026
- POINT72 ASSET MANAGEMENT, L.P. added 406,751 shares (+2259.9%) to their portfolio in Q1 2026, for an estimated $68,749,054
- FMR LLC added 385,373 shares (+32.6%) to their portfolio in Q1 2026, for an estimated $65,135,744
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
